title: [Clinical implications of the concentration and EGFR/KRAS mutations of plasma cell free DNA of patients with lung cancer and esophageal cancer].
abstract: OBJECTIVE
  To analyze the correlation between the concentration of plasma cell free DNA (cfDNA) of patients with lung cancer or esophageal cancer and clinical features, and to assess the coincidence rate of the EGFR/KRAS mutations between the cfDNA and tumor tissue DNA.
  
  
  METHODS
  A total of 30 cases lung cancer and esophageal cancer (including 15 lung cancer, 15 esophageal cancer) were enrolled in this study. The tumor tissue and plasma sample of patients were collected. The tumor tissue DNA and plasma cfDNA were extracted. The EGFR/KRAS mutations of the tumor tissue DNA and plasma cfDNA were detected by fluorescence PCR.
  
  
  RESULTS
  The concentration of cfDNA of patients with lung cancer (5.0 ± 1.4) μg/L and esophageal cancer (7.0 ± 0.8) μg/L were positively correlated with tumor size (r = 0.574, P = 0.01). There was no significant correlation between the concentration of cfDNA and TNM stage of tumor, gender, and age of patients. There was no EGFR/KRAS gene mutations in tumor tissue DNA and plasma cfDNA of esophageal cancer. A total of 6 tumor tissue samples of lung cancer patients were detected EGFR mutation, and 1 tumor tissue sample was detected KRAS mutation. Meanwhile, 4 plasma cfDNA samples of lung cancer patients were detected EGFR mutation, and 1 plasma cfDNA sample was detected KRAS mutation.
  
  
  CONCLUSIONS
  The concentration of cfDNA of patients with lung cancer and esophageal cancer was positively correlated with tumor burden. There was high coincidence rate of the EGFR/KRAS mutations between the cfDNA and tumor tissue DNA.
authors.forename: Ruixiang
authors.initials: R
authors.lastname: Zhang
authors.forename: Yin
authors.initials: Y
authors.lastname: Li
authors.forename: Yawei
authors.initials: Y
authors.lastname: Chen
authors.forename: Xianben
authors.initials: X
authors.lastname: Liu
authors.forename: Zongfei
authors.initials: Z
authors.lastname: Wang
authors.forename: Haibo
authors.initials: H
authors.lastname: Sun
authors.forename: Yan
authors.initials: Y
authors.lastname: Zheng
authors.forename: Zhidan
authors.initials: Z
authors.lastname: Ding
authors.forename: Ling
authors.initials: L
authors.lastname: Lan
authors.forename: Mingzhen
authors.initials: M
authors.lastname: Li
authors.forename: Jianjun
authors.initials: J
authors.lastname: Qin
authors.forename: Xiankai
authors.initials: X
authors.lastname: Chen
mesh_terms: D004247:DNA / Q000097:blood* / Q000235:genetics; D004252:DNA Mutational Analysis; D004273:DNA, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000235:genetics*; D004938:Esophageal Neoplasms / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D009154:Mutation; D016133:Polymerase Chain Reaction; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*
chemical_list: D004273:DNA, Neoplasm; C117307:KRAS protein, human; D004247:DNA; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras)